Jeffery D Molkentin1, Darrian Bugg2, Natasha Ghearing2, Lisa E Dorn2, Peter Kim2, Michelle A Sargent2, Jagadambika Gunaje2, Kinya Otsu2, Jennifer Davis1. 1. From Department of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital Medical Center, OH (J.D.M., N.G., L.E.D., M.A.S.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, OH (J.D.M); Department of Bioengineering, University of Washington, Seattle (D.B., P.K., J.G. J.D.); and Cardiovascular Division, King's College London British Heart Foundation Centre of Research Excellence, United Kingdom (K.O.). jeff.molkentin@cchmc.org jendavis@uw.edu. 2. From Department of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital Medical Center, OH (J.D.M., N.G., L.E.D., M.A.S.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, OH (J.D.M); Department of Bioengineering, University of Washington, Seattle (D.B., P.K., J.G. J.D.); and Cardiovascular Division, King's College London British Heart Foundation Centre of Research Excellence, United Kingdom (K.O.).
Abstract
BACKGROUND: In the heart, acute injury induces a fibrotic healing response that generates collagen-rich scarring that is at first protective but if inappropriately sustained can worsen heart disease. The fibrotic process is initiated by cytokines, neuroendocrine effectors, and mechanical strain that promote resident fibroblast differentiation into contractile and extracellular matrix-producing myofibroblasts. The mitogen-activated protein kinase p38α (Mapk14 gene) is known to influence the cardiac injury response, but its direct role in orchestrating programmed fibroblast differentiation and fibrosis in vivo is unknown. METHODS: A conditional Mapk14 allele was used to delete the p38α encoding gene specifically in cardiac fibroblasts or myofibroblasts with 2 different tamoxifen-inducible Cre recombinase-expressing gene-targeted mouse lines. Mice were subjected to ischemic injury or chronic neurohumoral stimulation and monitored for survival, cardiac function, and fibrotic remodeling. Antithetically, mice with fibroblast-specific transgenic overexpression of activated mitogen-activated protein kinase kinase 6, a direct inducer of p38, were generated to investigate whether this pathway can directly drive myofibroblast formation and the cardiac fibrotic response. RESULTS: In mice, loss of Mapk14 blocked cardiac fibroblast differentiation into myofibroblasts and ensuing fibrosis in response to ischemic injury or chronic neurohumoral stimulation. A similar inhibition of myofibroblast formation and healing was also observed in a dermal wounding model with deletion of Mapk14. Transgenic mice with fibroblast-specific activation of mitogen-activated protein kinase kinase 6-p38 developed interstitial and perivascular fibrosis in the heart, lung, and kidney as a result of enhanced myofibroblast numbers. Mechanistic experiments show that p38 transduces cytokine and mechanical signals into myofibroblast differentiation through the transcription factor serum response factor and the signaling effector calcineurin. CONCLUSIONS: These findings suggest that signals from diverse modes of injury converge on p38α mitogen-activated protein kinase within the fibroblast to program the fibrotic response and myofibroblast formation in vivo, suggesting a novel therapeutic approach with p38 inhibitors for future clinical application.
BACKGROUND: In the heart, acute injury induces a fibrotic healing response that generates collagen-rich scarring that is at first protective but if inappropriately sustained can worsen heart disease. The fibrotic process is initiated by cytokines, neuroendocrine effectors, and mechanical strain that promote resident fibroblast differentiation into contractile and extracellular matrix-producing myofibroblasts. The mitogen-activated protein kinase p38α (Mapk14 gene) is known to influence the cardiac injury response, but its direct role in orchestrating programmed fibroblast differentiation and fibrosis in vivo is unknown. METHODS: A conditional Mapk14 allele was used to delete the p38α encoding gene specifically in cardiac fibroblasts or myofibroblasts with 2 different tamoxifen-inducible Cre recombinase-expressing gene-targeted mouse lines. Mice were subjected to ischemic injury or chronic neurohumoral stimulation and monitored for survival, cardiac function, and fibrotic remodeling. Antithetically, mice with fibroblast-specific transgenic overexpression of activated mitogen-activated protein kinase kinase 6, a direct inducer of p38, were generated to investigate whether this pathway can directly drive myofibroblast formation and the cardiac fibrotic response. RESULTS: In mice, loss of Mapk14 blocked cardiac fibroblast differentiation into myofibroblasts and ensuing fibrosis in response to ischemic injury or chronic neurohumoral stimulation. A similar inhibition of myofibroblast formation and healing was also observed in a dermal wounding model with deletion of Mapk14. Transgenic mice with fibroblast-specific activation of mitogen-activated protein kinase kinase 6-p38 developed interstitial and perivascular fibrosis in the heart, lung, and kidney as a result of enhanced myofibroblast numbers. Mechanistic experiments show that p38 transduces cytokine and mechanical signals into myofibroblast differentiation through the transcription factor serum response factor and the signaling effector calcineurin. CONCLUSIONS: These findings suggest that signals from diverse modes of injury converge on p38α mitogen-activated protein kinase within the fibroblast to program the fibrotic response and myofibroblast formation in vivo, suggesting a novel therapeutic approach with p38 inhibitors for future clinical application.
Authors: Eric M Small; Jeffrey E Thatcher; Lillian B Sutherland; Hideyuki Kinoshita; Robert D Gerard; James A Richardson; J Michael Dimaio; Hesham Sadek; Koichiro Kuwahara; Eric N Olson Journal: Circ Res Date: 2010-06-17 Impact factor: 17.367
Authors: Oliver Bruder; Anja Wagner; Christoph J Jensen; Steffen Schneider; Peter Ong; Eva-Maria Kispert; Kai Nassenstein; Thomas Schlosser; Georg V Sabin; Udo Sechtem; Heiko Mahrholdt Journal: J Am Coll Cardiol Date: 2010-06-25 Impact factor: 24.094
Authors: Erin R Wissing; Justin G Boyer; Jennifer Q Kwong; Michelle A Sargent; Jason Karch; Elizabeth M McNally; Kinya Otsu; Jeffery D Molkentin Journal: Hum Mol Genet Date: 2014-05-29 Impact factor: 6.150
Authors: Yael Aschner; Meghan Nelson; Matthew Brenner; Helen Roybal; Keriann Beke; Carly Meador; Daniel Foster; Kelly A Correll; Paul R Reynolds; Kelsey Anderson; Elizabeth F Redente; Jennifer Matsuda; David W H Riches; Steve D Groshong; Ambra Pozzi; Jan Sap; Qin Wang; Dhaarmini Rajshankar; Christopher A G McCulloch; Rachel L Zemans; Gregory P Downey Journal: Am J Physiol Lung Cell Mol Physiol Date: 2020-06-03 Impact factor: 5.464
Authors: Mary C Regier; Emily Olszewski; Christoph C Carter; John D Aitchison; Alexis Kaushansky; Jennifer Davis; Erwin Berthier; David J Beebe; Kelly R Stevens Journal: Lab Chip Date: 2019-06-11 Impact factor: 6.799
Authors: Malina J Ivey; Jill T Kuwabara; Kara L Riggsbee; Michelle D Tallquist Journal: Am J Physiol Heart Circ Physiol Date: 2019-05-24 Impact factor: 4.733
Authors: Darrian Bugg; Ross Bretherton; Peter Kim; Emily Olszewski; Abigail Nagle; Austin E Schumacher; Nick Chu; Jagadambika Gunaje; Cole A DeForest; Kelly Stevens; Deok-Ho Kim; Jennifer Davis Journal: Circ Res Date: 2020-09-04 Impact factor: 17.367
Authors: Nehal J Patel; Drew M Nassal; Amara D Greer-Short; Sathya D Unudurthi; Benjamin W Scandling; Daniel Gratz; Xianyao Xu; Anuradha Kalyanasundaram; Vadim V Fedorov; Federica Accornero; Peter J Mohler; Keith J Gooch; Thomas J Hund Journal: JCI Insight Date: 2019-10-17